Establishment Labs Holdings Inc. (NASDAQ:ESTA) Given Average Recommendation of “Moderate Buy” by Analysts

Establishment Labs Holdings Inc. (NASDAQ:ESTA) has earned an average rating of “Moderate Buy” from the six brokerages that are covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating on the company. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is $58.83.

A number of research analysts have recently issued reports on the stock. Stephens reiterated an “overweight” rating and set a $68.00 price objective on shares of Establishment Labs in a report on Wednesday, August 7th. Citigroup boosted their price target on shares of Establishment Labs from $45.00 to $50.00 and gave the stock a “neutral” rating in a report on Tuesday, October 1st. JPMorgan Chase & Co. lowered their price objective on shares of Establishment Labs from $61.00 to $50.00 and set an “overweight” rating on the stock in a research report on Wednesday, August 7th. Finally, BTIG Research boosted their price target on shares of Establishment Labs from $62.00 to $65.00 and gave the company a “buy” rating in a research report on Monday, October 14th.

Establishment Labs Stock Performance

Shares of NASDAQ:ESTA opened at $48.12 on Friday. Establishment Labs has a 12-month low of $16.96 and a 12-month high of $60.12. The company has a quick ratio of 2.91, a current ratio of 4.44 and a debt-to-equity ratio of 4.30. The firm has a market cap of $1.34 billion, a PE ratio of -15.47 and a beta of 1.20. The company’s 50 day moving average price is $43.37 and its two-hundred day moving average price is $45.92.

Establishment Labs (NASDAQ:ESTA) last announced its earnings results on Tuesday, August 6th. The company reported ($0.62) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.11). Establishment Labs had a negative return on equity of 220.67% and a negative net margin of 54.97%. The firm had revenue of $44.12 million for the quarter, compared to the consensus estimate of $43.10 million. During the same period in the prior year, the business earned ($0.65) EPS. Establishment Labs’s quarterly revenue was down 9.2% on a year-over-year basis. Equities research analysts predict that Establishment Labs will post -2.27 earnings per share for the current year.

Hedge Funds Weigh In On Establishment Labs

Institutional investors and hedge funds have recently made changes to their positions in the business. Hood River Capital Management LLC bought a new stake in Establishment Labs during the 2nd quarter worth approximately $43,000. California State Teachers Retirement System raised its stake in Establishment Labs by 14.5% during the 1st quarter. California State Teachers Retirement System now owns 17,096 shares of the company’s stock worth $870,000 after acquiring an additional 2,167 shares during the period. Swiss National Bank raised its stake in Establishment Labs by 13.6% during the 1st quarter. Swiss National Bank now owns 37,500 shares of the company’s stock worth $1,909,000 after acquiring an additional 4,500 shares during the period. Nkcfo LLC bought a new stake in Establishment Labs during the 2nd quarter worth approximately $227,000. Finally, Concurrent Investment Advisors LLC bought a new stake in Establishment Labs during the 1st quarter worth approximately $263,000. Hedge funds and other institutional investors own 72.91% of the company’s stock.

About Establishment Labs

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.